Company profile for Contineum Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Contineum Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet medical needs. Our focus is on targeting biological pathways associated with specific clinical disabilities, aiming to modulate them in ways that can positively impact the course of disease. The c...
Contineum Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications with significant unmet medical needs. Our focus is on targeting biological pathways associated with specific clinical disabilities, aiming to modulate them in ways that can positively impact the course of disease. The company boasts a robust pipeline of internally developed programs aimed at addressing various NI&I disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
San Diego, CA 92121
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251211081244/en/Contineum-Therapeutics-Announces-Proposed-%2475.0-Million-Public-Offering

BUSINESSWIRE
11 Dec 2025

https://www.businesswire.com/news/home/20251124649214/en/Contineum-Therapeutics-to-Attend-the-8th-Annual-Evercore-Healthcare-Conference

BUSINESSWIRE
24 Nov 2025

https://www.biospace.com/drug-development/j-j-contineum-fail-risky-mid-stage-multiple-sclerosis-trial

BIOSPACE
21 Nov 2025

https://www.businesswire.com/news/home/20251120828592/en/Contineum-Therapeutics-Reports-Topline-Data-From-Its-Phase-2-PIPE-307-VISTA-Trial-for-the-Treatment-of-Relapsing-Remitting-Multiple-Sclerosis-RRMS

BUSINESSWIRE
20 Nov 2025

https://www.businesswire.com/news/home/20251030221332/en/Contineum-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-Affirms-Key-Clinical-Development-Milestones

BUSINESSWIRE
30 Oct 2025

https://www.pharmiweb.com/press-release/2025-09-18/contineum-therapeutics-reports-positive-topline-data-from-phase-1b-positron-emission-tomography-pet

PHARMAWEB
18 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty